Characterization of human S protein, an inhibitor of the membrane attack complex of complement. Demonstration of a free reactive thiol group.
about
Model for the three-dimensional structure of vitronectin: predictions for the multi-domain protein from threading and dockingAssignment of the four disulfides in the N-terminal somatomedin B domain of native vitronectin isolated from human plasmaThe changes in glycosylation after partial hepatectomy enhance collagen binding of vitronectin in plasmaIdentification of disulfide bonds in protein proteolytic degradation products using de novo-protein unique sequence tags approachMolecular cloning of S-protein, a link between complement, coagulation and cell-substrate adhesion.Ca2(+)-sensitive binding of thrombospondin to U937 cells is due to the formation of calcium precipitate in the binding medium.Molecular structure and functional characterization of a human complement cytolysis inhibitor found in blood and seminal plasma: identity to sulfated glycoprotein 2, a constituent of rat testis fluid.Fibrinogen-independent platelet adhesion and thrombus formation on subendothelium mediated by glycoprotein IIb-IIIa complex at high shear rate.SP-40,40, a newly identified normal human serum protein found in the SC5b-9 complex of complement and in the immune deposits in glomerulonephritis.Analysis of fibronectin receptor function with monoclonal antibodies: roles in cell adhesion, migration, matrix assembly, and cytoskeletal organizationIdentification of an Arg-Gly-Asp (RGD) cell adhesion site in human immunodeficiency virus type 1 transactivation protein, tatInhibition of cell adhesion by high molecular weight kininogen.Disulfides modulate RGD-inhibitable cell adhesive activity of thrombospondinHigh-affinity binding of the basement membrane proteins collagen type IV and laminin to the gastric pathogen Helicobacter pylori.Quantitation of vitronectin in serum: evaluation of its usefulness in routine clinical practice.The fibrinolytic system of the vessel wall and its role in the control of thrombosis.Protection of host cells by complement regulators.Regulation of complement.A deletion mutant of vitronectin lacking the somatomedin B domain exhibits residual plasminogen activator inhibitor-1-binding activitySpecific binding of the human S protein (vitronectin) to streptococci, Staphylococcus aureus, and Escherichia coli.Vitronectin binds to activated human platelets and plays a role in platelet aggregation.Role of Helicobacter pylori surface structures in bacterial interaction with macrophages.Endogenous cleavage of the Arg-379-Ala-380 bond in vitronectin results in a distinct conformational change which 'buries' Ser-378, its site of phosphorylation by protein kinase AMetals affect the structure and activity of human plasminogen activator inhibitor-1. I. Modulation of stability and protease inhibitionExpression of binding of plasminogen, thrombospondin, vitronectin, and fibrinogen, and adhesive properties by Escherichia coli strains isolated from patients with colonic diseases.Specific binding of urinary-type plasminogen activator (u-PA) to vitronectin and its role in mediating u-PA-dependent adhesion of U937 cells.In vivo clearance of ternary complexes of vitronectin-thrombin-antithrombin is mediated by hepatic heparan sulfate proteoglycans.New insights into heparin binding to vitronectin: studies with monoclonal antibodiesThe cluster of basic amino acids in vitronectin contributes to its binding of plasminogen activator inhibitor-1: evidence from thrombin-, elastase- and plasmin-cleaved vitronectins and anti-peptide antibodies.Formation, characterization and detection of a ternary complex between S protein, thrombin and antithrombin III in serum.Characterization of a site on PAI-1 that binds to vitronectin outside of the somatomedin B domain.Homology with hemopexin suggests a possible scavenging function for S-protein/vitronectin.Kinetic analysis of the interaction between vitronectin and the urokinase receptor.Plasminogen activator inhibitor type 1 promotes the self-association of vitronectin into complexes exhibiting altered incorporation into the extracellular matrix.Hydrolysis of platelet vitronectin by calpain.Type 1 plasminogen activator inhibitor induces multimerization of plasma vitronectin. A suggested mechanism for the generation of the tissue form of vitronectin in vivo.The cell adhesion domain in plasma vitronectin is cryptic.New insights into the size and stoichiometry of the plasminogen activator inhibitor type-1.vitronectin complex.Vitronectin inhibits blood platelet aggregation.Purification of vitronectin.
P2860
Q28206585-90CC41D1-B15B-4F6C-A352-BDA2CA80B613Q28264463-002A38AF-BDF6-4624-A01D-6BB4BDB7EF0DQ28565924-4269415A-DE61-4C28-8228-D29E2B7E345EQ30390914-089945F5-18A2-4A3A-A48E-FF0975DE9EBAQ33931976-A2A7026D-D653-4604-A589-81FB8396AC0FQ34176483-B779A4F4-71F2-43B5-8999-7C617A5EC942Q34304219-80D92414-5D57-407B-B699-8F5D6CD6C5BDQ34564820-8B4BA9A6-F713-40B6-80C4-7D2DE256B321Q35589951-98B7226C-3E6D-4AE0-9C38-A0DF88C4CEB1Q36221243-07DAB606-87B1-4610-8760-A9867B8F9640Q36223757-8680A957-57CD-4970-ADA0-23B6C3B3E98EQ36530787-00C2E95F-980B-4A02-B5A1-B26833478B45Q36531615-DC833D88-9427-4B8D-8E3C-180864FA5551Q36989807-697C9902-413D-4D31-93F7-869F8372B5E5Q37243691-71C332BE-BCB2-4A82-AAA7-3C29BFDBC589Q38000918-9764CDB1-757F-4DFB-9910-60B223BDE6ECQ38991019-0B738A95-38E2-45F3-8C4E-A683A5A6BDCBQ39628216-00510DFF-2B36-4807-AC4A-F537249F3633Q39782880-C0A53E8C-7498-4BCF-BD2A-EAE046BCF4B6Q40163829-88C4DCD7-02E2-4F23-8C4F-2CBCA44CB5C7Q40347050-721F7797-E559-41C5-A694-314973CD6B9FQ41139654-706204B5-3855-416A-AF75-C35DC750544AQ41781183-C23392B6-243D-4B5F-90E0-90417A71CD93Q41790954-908E91B3-561D-41AF-A874-C8388204AEBFQ41841202-25798549-47C4-4D69-AB2D-50893BD0FAC1Q41911335-F8E301FD-1574-4655-8C80-CBEB6E140037Q41925724-6DF63C71-FC13-4046-93D3-DECF1B0450A9Q41944844-343BD36D-C733-4159-965E-3F04D3203FDDQ42029455-72C8A83E-0A68-49B2-B1FA-E216B0DFCCE1Q42141307-59B02A79-9087-4E72-8098-47D4BA515216Q42588271-8161A629-B651-4B0E-8D58-8A557807DD06Q43561644-7C450D3E-A318-40E1-AE71-BCC18C176C07Q43843429-95988B11-CBA1-41C5-8DD9-52A237E3F0B8Q43858114-6ED4A0E8-156D-4BF9-84C8-807BD9951D4CQ45943510-C4C0CF46-41C8-41ED-B2A7-0A198FC08E2AQ45964408-84DD527B-1F90-412D-8527-97877EAE64AAQ46038258-A17F5EA6-799E-4236-9EF6-5774BBDD8F48Q47238554-2371F2F6-3128-4208-B2EB-BCA84020C109Q47776684-760856EF-3AD3-4B38-A3D3-BD50D1BD9AA0Q53296348-67C31E01-BDC9-4A7E-873A-29127AD58393
P2860
Characterization of human S protein, an inhibitor of the membrane attack complex of complement. Demonstration of a free reactive thiol group.
description
1985 nî lūn-bûn
@nan
1985 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1985 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1985年の論文
@ja
1985年論文
@yue
1985年論文
@zh-hant
1985年論文
@zh-hk
1985年論文
@zh-mo
1985年論文
@zh-tw
1985年论文
@wuu
name
Characterization of human S pr ...... f a free reactive thiol group.
@ast
Characterization of human S pr ...... f a free reactive thiol group.
@en
Characterization of human S pr ...... f a free reactive thiol group.
@nl
type
label
Characterization of human S pr ...... f a free reactive thiol group.
@ast
Characterization of human S pr ...... f a free reactive thiol group.
@en
Characterization of human S pr ...... f a free reactive thiol group.
@nl
prefLabel
Characterization of human S pr ...... f a free reactive thiol group.
@ast
Characterization of human S pr ...... f a free reactive thiol group.
@en
Characterization of human S pr ...... f a free reactive thiol group.
@nl
P356
P1433
P1476
Characterization of human S pr ...... f a free reactive thiol group.
@en
P2093
P304
P356
10.1021/BI00330A036
P407
P577
1985-04-01T00:00:00Z